外周T细胞淋巴瘤24个月无事件生存期的国际评估及后续生存
该研究纳入2000至2012年新诊断并接受根治性治疗的全身性外周T细胞淋巴瘤患者775例,来自美国、瑞典(初始队列)和加拿大(重复队列),评估24个月无事件生存期(EFS24)及后续总生存(OS)。64%的患者在24个月内进展,中位OS仅4.9个月;达到EFS24者中位OS未达到,5年OS为78%,但仍有23%在达到EFS24后5年内复发。
要点
- 64%的PTCL患者在24个月内进展,中位OS仅4.9个月(5年OS 11%)。
- 达到EFS24者中位OS未达到,5年OS为78%,但23%在5年内复发。
- ≤60岁患者达到EFS24后5年OS为91%,年轻患者预后更优。
核心结论
- EFS24可对PTCL后续结局进行分层,原发难治或早期复发患者生存极差,而超过三分之一患者在诊断后2年仍缓解且后续OS令人鼓舞,尤其年轻患者。
- 这些结局的显著差异提示EFS24可用于患者咨询、研究设计和风险分层。
研究设计与样本
- 多国队列研究,纳入2000至2012年新诊断并接受根治性治疗的全身性PTCL患者,来自美国、瑞典(初始队列)和加拿大(重复队列),共775例,诊断时中位年龄64岁,63%为男性。
- EFS定义为从诊断日期至原发治疗后进展、再治疗或死亡的时间;后续OS在达到EFS24后或若24个月内进展则从进展时测量,并与年龄、性别和国家匹配的一般人群比较OS率。
主要发现
- 初始队列与重复队列结果相似,遂进行联合分析。
- 64%的患者在最初24个月内进展,其中位OS仅4.9个月(5年OS 11%)。
- 达到EFS24后中位OS未达到(5年OS 78%),但达到EFS24后5年内复发者占23%。
- 达到EFS24后,年轻患者(≤60岁)的5年OS为91%。
关键数值与推荐
- EFS24定义为从诊断日期至原发治疗后进展、再治疗或死亡的时间。
- 进展患者(64%)中位OS 4.9个月(5年OS 11%);达到EFS24者中位OS未达到(5年OS 78%),23%在达到EFS24后5年内复发。
- ≤60岁达到EFS24者5年OS为91%。
临床怎么用
- 作者认为EFS24可用于PTCL患者咨询、研究设计和风险分层。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Peripheral T-cell lymphomas (PTCLs) have aggressive clinical behavior. We have previously shown that event-free survival (EFS) at 24 months (EFS24) is a clinically useful end point in diffuse large B-cell lymphoma. Here, we assess EFS24 and subsequent overall survival (OS) in large, multinational PTCL cohorts. Patients and Methods Patients with systemic PTCL newly diagnosed from 2000 to 2012 and treated with curative intent were included from the United States and Sweden (initial cohorts) and from Canada (replication cohort). EFS was defined as time from date of diagnosis to progression after primary treatment, retreatment, or death. Subsequent OS was measured after achieving EFS24 or from the time of progression if it occurred within 24 months. OS rates were compared with the age-, sex-, and country-matched general population. Results Seven hundred seventy-five patients were included in the study (the median age at diagnosis was 64 years; 63% were men). Results were similar in the initial and replication cohorts, and a combined analysis was undertaken. Sixty-four percent of patients progressed within the first 24 months and had a median OS of only 4.9 months (5-year OS, 11%). In contrast, median OS after achieving EFS24 was not reached (5-year OS, 78%), although relapses within 5 years of achieving EFS24 occurred in 23% of patients. Superior outcomes after achieving EFS24 were observed in younger patients (≤ 60 years of age: 5-year OS, 91%). Conclusion EFS24 stratifies subsequent outcome in PTCL. Patients with PTCL with primary refractory disease or early relapse have extremely poor survival. However, more than one third of patients with PTCL remain in remission 2 years after diagnosis with encouraging subsequent OS, especially in younger patients. These marked differences in outcome suggest that EFS24 has utility for patient counseling, study design, and risk stratification in PTCL.
引用
- Maurer MJ, Ellin F, Srour L, et al. International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. J Clin Oncol. 2017. PMID: 29072976. doi:10.1200/JCO.2017.73.8195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。